Thane-based has acquired an 85 per cent equity stake in Ahmedabad-based Arinna Lifesciences Limited, marking its entry into India’s domestic formulations market, with a focus on the central nervous system (CNS) therapeutic segment.
The transaction values Arinna at an enterprise value of ₹200 crore on a cash- and debt-free basis. After factoring in net cash and other adjustments, the purchase consideration stands at approximately ₹175.92 crore for the secondary acquisition, translating to ₹158.53 per share, the company stated in an official release.
As part of the deal, Arinna’s founder Vivek Seth will retain a 15 per cent stake in the company and continue as its Managing Director.
The transaction is expected to close within 30 days, subject to the fulfilment of customary conditions precedent.
Ahmedabad-based Arinna is a branded pharmaceutical marketing company focused on CNS and neuro-psychiatric therapies, with a portfolio of over 60 brands spanning antiepileptics, antidepressants and antipsychotics. The company has built a network of more than 4,000 prescribers, supported by an established distribution ecosystem comprising distributors, stockists and retail pharmacies across India.
For the financial year ended March 2025, Arinna reported turnover of ₹71.5 crore. For the nine months ended December 2025, it posted provisional revenue of ₹56.7 crore and EBITDA of ₹9.5 crore.
The acquisition aligns with Rubicon’s strategy of leveraging its intellectual property and chronic product portfolio to expand in key therapeutic areas, particularly CNS, which has been a core focus for the company.
Rubicon, an integrated pharmaceutical company with operations spanning research and development, manufacturing and commercialisation, has been expanding its presence across markets. The company has a portfolio of over 80 products and operates globally inspected manufacturing facilities regulated by agencies such as the US FDA, UK MHRA and Australia’s TGA.
Arinna’s domestic sales and distribution platform is expected to provide Rubicon access to Indian patients and prescribers for its differentiated offerings, including specialty products and drug-device combinations currently in its pipeline.